Concepedia

Author

Panteli Theocharous

Hospices Civils de Lyon

Also Known As

P. Theocharous, PANTELI THEOCHAROUS, Panteli THEOCHAROUS, Panteli Theocharous, Theocharous, P

45

Publications

2.2K

Citations

10

H-Index

13

Concepts

All Affiliations

Hospices Civils de LyonJanssen (United Kingdom)Millennium Engineering and Integration (United States)The Maria Sklodowska-Curie National Research Institute of OncologyDerriford Hospital
PT

About

Panteli Theocharous is an author at Hospices Civils de Lyon specializing in medicine, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

2K

2

Pathology

3

3

2K

3

Immunology

2

2

275

4

Medical Laboratory Science

1

1

265

5

Hematology

1

1

265

Panteli Theocharous

×

10

Publications

2.2K

Citations

10

H-Index

YearCitations

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong,

The Lancet Oncology

2011

1.6K

Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells

Elin Borgen, Bjørn Naume, Jahn M. Nesland,

Cytotherapy

1999

265

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong,

The Lancet Oncology

2011

108

Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG ± Ida) and second allogeneic stem cell transplant

Rachel Pawson, Mike Potter, Panteli Theocharous,

British Journal of Haematology

2001

73

Baculovirus‐mediated expression and characterisation of rat glycogen synthase kinase‐3β, the mammalian homologue of the <i>Drosophila melanogaster zeste‐white 3<sup>sgg</sup></i>, homeotic gene product

Kenneth Hughes, Bernd Pulverer, Panteli Theocharous,

European Journal of Biochemistry

1992

56

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase <scp>III</scp> trial

Ruth Pettengell, Catherine Sebban, Pier Luigi Zinzani,

British Journal of Haematology

2016

28

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

Pier Luigi Zinzani, Nuriet K. Khuageva, Huaqing Wang,

Journal of Hematology & Oncology

2012

21

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Bertrand Coiffier, Weimin Li, Erin D. Henitz,

Clinical Cancer Research

2013

18

A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma

Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong,

Blood

2010

12

A novel murine model of allogeneic vaccination against prostate cancer

Marie-Christine Labarthe, Panteli Theocharous, Nicholas Russell,

Cancer Immunology Immunotherapy

2007

10

Page 1